Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Donald Hayden?

Donald J. Hayden

Chairman

Insmed Incorporated

HQ Phone:  (908) 977-9900

Direct Phone: (804) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Insmed Incorporated

10 Finderne Avenue Building 10

Bridgewater, New Jersey,08807

United States

Company Description

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two iden...more

Background Information

Employment History

Director

Otsuka America Pharmaceutical , Inc.


Chairman

Vitae Pharmaceuticals Inc


Executive Vice President and President, Americas

Bristol-Myers Squibb Company


Director of New Business Development and Planning

USA Pharmaceutical Group


Affiliations

REGENXBIO Inc.

Chairman


Amicus Therapeutics Inc

Chairman


Prospect Venture Partners

Senior Advisor


Gloucester Pharmaceuticals Inc

Chairman


Governance Committee

Member


Nominations

Member


WindMIL Therapeutics

Board Member


Alvine Pharmaceuticals Inc

Board Member


Executive Chairman of Azelon Pharmaceuticals , Chairman

Board Member


CancerCare Inc

Board of Trustees Member


Cambridge , MA - February 20 , 2007 -

Vice Chairman


Satori Pharmaceuticals Incorporated

Board Member


Transave , Inc.

Chairman


Education

BA

Harvard University


Masters of Business Administration degree

Indiana University


Web References(175 Total References)


Azelon gets financing for osteoporosis nasal spray, adds to management team

www.oindpnews.com [cached]

The company also named Joan Lau as its new president and CEO, succeeding Brian MacDonald, and Don Hayden as Executive Chairman.
Lau was previously CEO of Locus Pharmaceuticals; Hayden is a former Executive VP and President, Americas of Bristol-Myers Squibb and is currently Chairman of Insmed and Lead Director at Amicus Therapeutics.


BOARD OF DIRECTORS - Insmed

www.insmed.com [cached]

Donald J. Hayden, Jr.
Donald J. Hayden, Jr. Chairman of the Board Mr. Hayden has been the non-Executive Chairman of our Board since December 2010, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. He previously served as chairman of the board for Vitae Therapeutics (Nasdaq: VTAE) from 2006 to 2016 until its acquisition by Allergan plc (NYSE: AGN). Mr. Hayden currently serves as chairman of the board of REGENXBIO (Nasdaq: RGNX) as well as lead independent director of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden also serves on the board of directors for the privately-held company WindMIL Therapeutics. Mr. Hayden also serves as a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.


Board of Directors - Insmed

investor.insmed.com [cached]

Donald J. Hayden Jr.
Donald J. Hayden Jr. Chairman of the Board Mr. Hayden has been the non-Executive Chairman of our Board since December 2010, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. He previously served as chairman of the board for Vitae Therapeutics (Nasdaq: VTAE) from 2006 to 2016 until its acquisition by Allergan plc (NYSE: AGN). Mr. Hayden currently serves as chairman of the board of REGENXBIO (Nasdaq: RGNX) as well as lead independent director of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden also serves on the board of directors for the privately-held company WindMIL Therapeutics. Mr. Hayden also serves as a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Inc. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.


Leadership Team: Amicus Therapeutics

www.amicusrx.com [cached]

Donald J. Hayden , Jr. Lead Independent Director
Donald J. Hayden , Jr. Lead Independent Director Donald J. Hayden, Jr. has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010. Mr. Hayden served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several executive positions with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr. Hayden is Senior Advisor to Prospect Venture Partners, a life sciences venture capital firm, since 2006 and is a member of the Board of Directors of Insmed Incorporated, Vitae Pharmaceuticals, Regenexbio and Otsuka (Tokyo). Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University.


BOARD OF DIRECTORS - Insmed

www.insmed.com [cached]

Donald J. Hayden, Jr.?
Donald J. Hayden, Jr. Chairman of the Board Mr. Hayden has been a member of our Board since December 2010. Mr. Hayden has been the non-Executive Chairman of our Board since December 2010, except for the period from May 2012 to September 2012, when he acted as our Executive Chairman during a transition of senior level management. He previously served as the Executive Chairman of Transave, a biotechnology company, from 2006 until 2010, when Transave was acquired by Insmed. From 1981 to 2006, Mr. Hayden was an executive with Bristol-Myers Squibb Company, where he served in key executive roles including President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. Mr. Hayden currently serves as chairman of the boards of ReGenXBIO (Nasdaq: RGNX) and Vitae Pharmaceuticals (Nasdaq: VTAE), as well as lead independent director of Amicus Therapeutics (Nasdaq: FOLD). Mr. Hayden also chairs the board of Nora Therapeutics, a privately held company, and serves as a director of Otsuka America Pharmaceuticals, Inc., the U.S. subsidiary of Otsuka Pharmaceutical Company, Limited. Mr. Hayden is a senior advisor to Prospect Venture Partners, a venture capital firm. Mr. Hayden holds a Bachelor of Arts degree in general studies from Harvard University and a Masters of Business Administration degree from Indiana University. Mr. Hayden is a member of the Nominations and Governance Committee.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory